1. Introduction
In recent years, the INCI name "Oligopeptide-1" has appeared with increasing frequency in cosmetic ingredient procurement, driven by its association with claims such as "repair," "anti-aging," and "cell regeneration." However, buyers face a fundamental reality: the Oligopeptide-1 found in international markets and the "寡肽-1" (Oligopeptide-1) recognized under Chinese regulations are not the same substance in terms of chemical structure, molecular weight, or regulatory status.
Under the international INCI system, Oligopeptide-1 typically refers to recombinant human epidermal growth factor (EGF), a 53-amino-acid peptide with a molecular weight of approximately 6200 Da. In the medical field, it is used to promote chronic wound healing and tissue repair. In China, EGF has been explicitly prohibited for use as a cosmetic ingredient by the National Medical Products Administration (NMPA). Meanwhile, the "寡肽-1" listed in China's "Catalogue of Used Cosmetic Raw Materials" is a synthetic tripeptide (GHK) composed of glycine, histidine, and lysine, with a molecular weight of approximately 340 Da. The two are fundamentally different.
This disconnect between international nomenclature and Chinese regulatory definitions creates compliance risks in B2B sourcing. Many overseas suppliers sell Oligopeptide-1 labeled as "EGF" or "recombinant human epidermal growth factor," which is compliant in European and US markets but violates Chinese regulations when imported for cosmetic manufacturing. Domestically, some suppliers also blur the line by using EGF medical literature to promote "寡肽-1" raw materials, further complicating procurement decisions.
2. What Exactly Is Oligopeptide-1 in International Markets?
Under the International Nomenclature of Cosmetic Ingredients (INCI) system, Oligopeptide-1 typically refers to a specific bioactive molecule-recombinant human epidermal growth factor (EGF).
EGF is a 53-amino-acid peptide with a molecular weight of approximately 6200 Da. Its mechanism of action is well understood: it binds to the epidermal growth factor receptor (EGFR) on the cell surface, activates downstream signaling pathways, and promotes the proliferation, differentiation, and migration of epidermal cells and fibroblasts. In the medical field, it is used to treat burns, wounds, and chronic ulcers, significantly accelerating wound healing and tissue regeneration.
According to a 2026 market research report, the global Oligopeptide-1 (EGF) market was valued at approximately $315 million in 2024 and is projected to reach $579 million by 2032, with a CAGR of about 7.8%. Key application areas include anti-aging, skin repair, and regeneration products, with end users primarily in cosmetics and personal care brands.
However, it is important to note that "Oligopeptide-1" in international markets typically refers to EGF, while the "寡肽-1" listed in China's cosmetic ingredient catalogue is a different substance with distinct chemical structure, molecular weight, and regulatory status.
3. China's Regulatory Red Line: Why Is EGF Prohibited?
In January 2019, the NMPA issued the "Common Questions and Answers on Cosmetic Supervision (No. 1)," making two key clarifications: first, that "Oligopeptide-1" and " EGF" are not the same substance; and second, that human oligopeptide-1 (EGF) cannot be used as a cosmetic ingredient.
The prohibition of EGF in cosmetics is based on two primary considerations:
Large molecular weight, poor penetration through intact skin. EGF has a molecular weight of approximately 6200 Da, well above the commonly cited 500 Da threshold for transdermal absorption. On healthy skin with an intact barrier, EGF struggles to penetrate the stratum corneum to reach its target cells.
Safety risks when the skin barrier is compromised. When the skin is damaged, inflamed, or has impaired barrier function, EGF may penetrate deeply into the skin, excessively activate the EGFR pathway, and theoretically pose a risk of abnormal proliferation.
In contrast, the "Oligopeptide-1" recognized under Chinese regulations is a completely different substance. It is a synthetic peptide (GHK tripeptide) composed of glycine, histidine, and lysine, with a molecular weight of approximately 340 Da, and is listed as a skin conditioning agent in the "Catalogue of Used Cosmetic Raw Materials."
4. The Regulatory Disconnect – Compliance Risks in Procurement
This definitional disconnect is exactly where B2B procurement is most prone to compliance errors.
Many overseas suppliers sell Oligopeptide-1 labeled directly as "EGF" or "recombinant human epidermal growth factor," which is compliant in European and US markets. In international markets, Oligopeptide-1 generally refers to recombinant human EGF, and some suppliers classify it under "Oligopeptide-1." Some formulators promote sh-Oligopeptide-1-containing formulations as "active ingredients that promote skin repair and regeneration," often combining them with polyphenolic extracts to enhance skin barrier function. However, when imported into China for cosmetic manufacturing, these materials run into regulatory barriers-EGF is a prohibited cosmetic ingredient in China.
When sourcing, the following verification points are critical:
Request a COA from the supplier that clearly specifies the chemical structure, molecular weight, and amino acid sequence of the material.
Confirm that the INCI name matches the "寡肽-1" listed in China's "Catalogue of Used Cosmetic Raw Materials".
For materials labeled "sh-Oligopeptide-1," verify whether the substance corresponds to EGF.
Request a declaration from the supplier confirming that the raw material is not derived from EGF.
Additionally, the "General Technical Requirements for Biotech-Derived Cosmetic Ingredients" (YY/T10001-2026), effective May 2027, will further refine compliance requirements for peptide-based biological ingredients. Raw material suppliers should prepare their technical documentation in advance.
5. What Can Compliant Oligopeptide-1 (GHK) Do?
Returning to the compliant "GHK tripeptide" under Chinese regulations, its mechanism of action in formulations is clear and verifiable. As a matrikine (signaling peptide), it mimics signal molecules released after skin injury, guiding fibroblasts to synthesize extracellular matrix components such as collagen, elastin, and glycosaminoglycans.
The efficacy data for GHK tripeptide is primarily concentrated on stimulating collagen synthesis, improving skin elasticity, and firming. A 2024 human clinical study showed that a compound cream containing sh-Oligopeptide-1 significantly increased skin hydration (p<0.000) and improved skin elasticity (p=0.042) after one week of use on healthy volunteers.
|
Comparison |
International Oligopeptide-1 (EGF) |
Compliant "寡肽-1" (GHK) |
|
Chemical structure |
53 amino acids |
3 amino acids |
|
Molecular weight |
~6200 Da |
~340 Da |
|
Mechanism |
EGFR receptor agonist |
Signaling peptide / Matrikine |
|
China cosmetic regulation |
Prohibited |
Listed in Used Ingredients Catalogue |
6. B2B Sourcing Recommendations
Do not place orders based solely on the name. When you see "Oligopeptide-1" first confirm which substance the supplier is providing-the 53-amino-acid EGF or the 3-amino-acid GHK tripeptide. Their compliance status is completely different.
Request structural confirmation documentation. Reputable suppliers should be able to provide structural confirmation data including molecular weight, amino acid sequence, and HPLC fingerprints.
Be cautious with "repair" and "regeneration" claims. The medical repair effects of EGF cannot be directly transferred to compliant GHK tripeptide. If a supplier uses EGF medical literature to promote "寡肽-1" raw materials, a careful review is warranted.
7. Conclusion & Contact Information
The name Oligopeptide-1 refers to different substances under international and Chinese regulatory frameworks. Buyers need to understand which substance they actually require, rather than ordering based on the name alone. The compliant "寡肽-1" (GHK tripeptide) has been included in the "Catalogue of Used Cosmetic Raw Materials" and can be used as a skin conditioning agent in cosmetics.
Landnutra (Xi'an Land Nutra Co., Ltd.) supplies cosmetic-grade Oligopeptide-1 raw materials that strictly comply with China's Used Cosmetic Raw Materials Catalogue requirements, supporting INCI name filing and formulation application development:
Raw material source: Chemically synthesized, non-EGF origin
Compliance: Listed in the "Catalogue of Used Cosmetic Raw Materials (2021 Edition)"
Water solubility: Good, suitable for serums, masks, creams, and other formulations
Recommended dosage: 2-10% (1000 ppm stock solution)
Packaging: Customized according to customer requirements
Full COA and supporting compliance documentation
Contact us for:
Free technical samples
Batch-specific COA and compliance documentation
Regulatory guidance for China, EU, and US markets
Email: wangjing@landnutra.com
WhatsApp: +86 18092657549
Landnutra – Making every ingredient's compliance identity stand up to scrutiny, serving global brands with science-backed supply chain solutions.
References
1.European Commission. COSING – Cosmetic Ingredients Database.
2.Cosmetic Ingredient Review (CIR). Safety Assessment of Oligopeptide-1 as Used in Cosmetics.
3.NCATS Inxight Drugs. Prezatide (GHK) – Drug Summary.
4.National Institutes of Health (NIH). PubChem – GHK Peptide.
5.Mayayo T, Russo G, Jiménez-Escobar AL, et al. Microencapsulation, Cream Development, and Controlled Clinical Study of an Upcycled Polyphenolic Extract Combined with sh-Oligopeptide-1. Cosmetics. 2024;11(6):198.